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Abstract The TAM receptors are a distinct family of three receptor tyrosine kinases, namely Tyro3, Axl, and MerTK. Since
their discovery in the early 1990s, they have been studied for their ability to influence numerous diseases, including
cancer, chronic inflammatory and autoimmune disorders, and cardiovascular diseases. The TAM receptors demon-
strate an ability to influence multiple aspects of cardiovascular pathology via their diverse effects on cells of both
the vasculature and the immune system. In this review, we will explore the various functions of the TAM receptors
and how they influence cardiovascular disease through regulation of vascular remodelling, efferocytosis and inflam-
mation. Based on this information, we will suggest areas in which further research is required and identify potential
targets for therapeutic intervention.
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1. Introduction
Insight from the results of studies using cultured cells, mouse models of
cardiovascular disease subjected to genetic engineering or pharmacolog-
ical intervention, and observational studies in humans have provided
strong evidence that the immune responses plays an important role in
cardiovascular pathologies.1–3 Most importantly, the CANTOS trial
(Canakinumab Anti-inflammatory Thrombosis and Outcomes Study)
has recently demonstrated the efficacy of targeting interleukin (IL)-1b
for reducing secondary cardiovascular events,4 and therefore, much of
current research is now focusing on how to limit inflammation to pre-
vent cardiovascular diseases (CVD).
Among the many molecules that influence the immune response, the
TAM family of tyrosine kinase receptors have demonstrated a capacity
to influence the function of both the vascular and immune system in the
steady state and in pathology. Accordingly, there has been much interest
in their potential roles in CVD and how they may be viewed as potential
therapeutic targets. This family of proteins includes Tyro3, Axl, and
MerTK, with the first letters of each giving the family its name.5 They
remained orphan receptors for the first few years following their
discovery, but by the mid-1990’s their ligands were identified as growth
arrest-specific 6 (Gas6) and Protein S (Pros1).6,7 These ligands bind to
the TAM receptors with differential affinity. Gas6 can associate with all
three receptors, but with strongest affinity to Axl, then Tyro3, and with
lower affinity to MerTK.6 Pros1, however, does not bind to Axl at all,
and has stronger affinity binding with Tyro3 than MerTK.8
2. TAM receptors
2.1 Structure
The basic structure of the TAM receptors includes an extracellular N-
terminal region containing two immunoglobulin (Ig)-like domains, fol-
lowed by two fibronectin type III (FNIII) domains, a hydrophobic domain
which traverses the cell membrane, and finally, an intracellular tyrosine
kinase C-terminal domain.9,10 The Gas6 and Pros1 ligands possess an ap-
proximately 50 amino acid stretch which contains gamma carboxylated
glutamic acid residues, referred to as the Gla-domain. These residues
have a high affinity for calcium, which facilitates binding to phosphatidyl-
serine (PtdSer) molecules found on the surface of platelets and on the
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outer leaflet of cell membranes under certain conditions, notably on
apoptotic cells.11 The C-terminus of the ligands possess laminin G (glob-
ular) domains, which facilitate their interactions with the TAM receptor
Ig-like domains.12 As for most receptor tyrosine kinases (RTKs), activa-
tion of the TAM receptors occurs via ligand facilitated dimerization,
which mediates autophosphorylation of their tyrosine kinase domain.9
This results in coupling of the receptor with proteins involved in signal-
ling pathways, which will be discussed in more detail below.
2.2 TAM receptor functions
Remarkably, TAM receptors are not required for embryonic develop-
ment, which is unusual for one RTK, let alone an entire subset.13
However, this property enabled the generation of viable triple TAM
knock-out (KO) mice, which propelled studies exploring the functions of
the TAM receptor family. When these KO mice reach adulthood, three
distinct phenotypes can be observed. The first is male infertility, which
occurs due to an inability to clear apoptotic gamete cells in the testes.13
The second phenotype is blindness due to retinal epithelial cells not be-
ing able to engulf the outer segments of the photoreceptors, which is
necessary for the removal of toxic byproducts of phototransduction.14
The third phenotype is autoimmunity.15–18 This stems from the require-
ment to clear the apoptotic bodies generated during the immune
response in order to resolve inflammation.19 Failure to clear dead cells
can cause them to become necrotic, with their accumulation serving as a
source of self-antigen.20
Phagocytosis of apoptotic cells (efferocytosis) is a fundamental pro-
cess for the restoration of immune and tissue homeostasis,21 and the
TAM receptors play an important role in efferocytosis in adult
tissues.22,23 In atherosclerosis, efferocytosis is required for clearing of
apoptotic cells in lesions, and in advanced atherosclerosis, this process
can go awry, leading to post-apoptotic necrosis of lesional cells.24–28 This
pathological process can lead to large areas of plaque necrosis, which are
highly inflammatory and render the plaques susceptible to rupture or
erosion. Ruptured or eroded plaques can then promotes occlusive vas-
cular thrombosis, leading to acute coronary syndromes such as myocar-
dial infarction (MI), unstable angina, sudden cardiac death, or stroke.29 In
atherosclerosis, efferocytosis is largely orchestrated by professional
phagocytes such as macrophages, which are known to express and uti-
lize TAM receptors in this process.30–32 In other settings, it is likely that
the non-professional phagocytes including cardiac myofibroblasts and
epithelial cells also express TAM receptors,33,34 particularly Axl which
shows high levels of expression in the heart.35,36
In addition to the anti-inflammatory effects of efficient efferocytosis,
the TAM receptors are involved in directing the change in the immune
response from attack-the-pathogen to repair-and-restore (reso-
lution).16,37 This was first indicated by the phenotype of the triple TAM
receptor KO mice, which develop a lymphoproliferative disorder and
broad-spectrum autoimmunity driven by chronic hyper-activation of an-
tigen presenting cells such as monocytes, dendritic cells (DCs), and
macrophages.15
Expression of TAM receptors is up-regulated in innate immune cells
upon their activation in order to prime the system for negative feedback,
which is subsequently facilitated by the increased availability of their
ligands upon initiation of the adaptive response.10 Upon ligand-mediated
autophosphorylation, TAM receptors can physically associate with the
type I interferon receptor (IFNAR)-STAT1 complex, which normally
drives the initial amplification of inflammation. However, the association
between the R1 subunit of IFNAR and the phosphorylated TAM causes
a change in the function of the IFNAR-STAT1 complex to that of an
anti-inflammatory signalling molecule, which in turn initiates transcription
of the suppressor of cytokine signalling (SOCS)1 and SOCS3 proteins.16
These proteins ultimately suppress both cytokine receptor and Toll-Like
receptor (TLR)3, TLR4, and TLR9 pro-inflammatory signalling
pathways.38 This relationship between TAM receptors and ligands is key
to maintaining immune homeostasis, particularly between T cells, which
produce Pros1 upon activation, and DCs expressing the TAM
receptors.39 T cell-DC interactions have been shown to occur within
atherosclerotic lesions, which can enhance the pro-inflammatory nature
of the plaque.40–42 Therefore, deregulation of TAM-mediated suppres-
sion and resolution of the inflammatory response can strongly influence
cardiovascular immunity.
2.3 Regulation of TAM receptor expression
The expression and activity of the TAM receptors are controlled by vari-
ous factors at the transcriptional, post-transcriptional, and protein levels.
Induction of specific TAM receptor genes can be mediated by various
cytokines. For example, transforming growth factor b (TGF-b), and
granulocyte-macrophage colony-stimulating-factor, and several proin-
flammatory stimuli can drive Axl expression, while IL-17A, IL-10, and
dexamethasone drive MerTK expression.43–46 As Tyro3 has not been
closely studied in the context of inflammation or the immune response,
it remains unclear which cytokines, if any, specifically up-regulate its
expression.
Up-regulation of MerTK expression can also be induced by glucocor-
ticoids and the liver-X-receptors (LXR) a and b.47,48 TAM receptor reg-
ulation by the LXRs is of interest in CVD due to their role in cholesterol
biosynthesis and homeostasis, notably cholesterol efflux from
macrophages.49
As an example of another level of regulation, microRNA-34a has
been demonstrated to suppress protein expression of Axl, and this pro-
cess can contribute to the autoimmune disorder rheumatoid arthritis.50
Similarly, microRNA-7 inhibits Tyro3 expression and is consequently be-
ing explored as an RNA-based therapeutic for treating abhorrent Tyro3
overexpression in human hepatocellular carcinoma.51
Once TAM receptors are fully synthesized, inserted into the plasma
membrane, and activated, their extracellular domain can be cleaved by
the metalloprotease A Disintegrin And Metalloproteinase (ADAM)-
17.52,53 This cleavage liberates a soluble extracellular domain bound to li-
gand (sAxl or sMer) and destroys TAM receptor function. Conversely,
secretory leucocyte protease inhibitor increases the expression of
MerTK on the cell surface, likely by inhibiting its cleavage.54 The molecu-
lar regulation of TAM receptors is illustrated in Figure 1.
3. Axl in CVD
3.1 Gas6-Axl and regulation of
cardiovascular remodelling
Vascular remodelling refers to a dynamic process that causes changes to
the structure of the vascular wall. This can occur in response to certain
stimuli, such as injury or local production of inflammatory mediators. In
addition, chronic conditions such as hypertension or atherosclerosis can
drive the process of vascular remodelling. Although vascular remodelling
likely represents a response to correct environmental changes to vascu-
lar flow and maintain homeostasis, it can have pathological effects, as de-
scribed below. Several vascular cell types, including endothelial cells
(ECs), vascular smooth muscle cells (VSMCs), fibroblasts and myofibro-
blasts, contribute to vascular remodelling. Vascular remodelling occurs
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and extracellular matrix synthesis and degradation. For each of these
processes, Axl and its ligands have been shown to play a role, while the
contributions of MerTK and Tyro3 are less clear.
Both Pros1 and Gas6 were shown to be secreted by and enhance the
proliferation of VSMCs prior to their identification as the ligands for
TAM receptors.58,63 Subsequently, Axl expression was found to be in-
creased in VSMCs following balloon-injury in rat carotid artery, and both
Axl and Gas6 expression were temporally correlated with neointima
formation.64 The key role of Gas6/Axl pathway in the regulation of vas-
cular remodelling was confirmed in animal studies, which showed re-
duced intimal thickening following vascular injury in Axl-/- mice
compared with wild type control mice.59,65,66 Similarly, in the deoxycor-
ticosterone acetate (DOCA)-salt hypertensive mouse model, Axl defi-
ciency led to reduced systolic blood pressure67,68 and reduced
remodelling index of the mesenteric artery.68 Emerging studies suggest
Figure 1 Molecular regulation of the TAM receptors. The expression and activity of the TAM receptors is controlled by various factors at the tran-
scriptional, post-transcriptional, and protein levels. (A) TAM receptor gene transcription can be up- or down-regulated by various factors, including cyto-
kines. The figure shows mediators that specifically regulate MerTK transcription; the other TAM receptors are regulated by other mediators.43,44,46–48 (B)
Post-transcriptional regulation by micro-RNAs such as miR-34a inhibition of Axl expression.50 (C) At the protein level, TAM receptors are rendered dys-
functional by cleavage of their extracellular domain by metalloprotease ADAM17.52,53 This process which can be driven by other environmental factors
such as reactive oxygen species (ROS).53,55,56 (D) The soluble byproduct released may act as a decoy for the receptor ligands, thus inhibiting TAM recep-
tor activity.57 (E) Activation of the receptors can also be enhanced by various environmental factors.58–60 (F) Activation of the TAM receptors subse-
quently induces various molecular pathways affecting cell function.16,60–62
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that (i) induction of proliferation of VSMCs,58,63 (ii) stimulation of migra-
tion of VSMCs,69 and (iii) protection from apoptosis70,71 are underlying
mechanisms linking Gas6/Axl signalling to vasculature remodelling.
Angiotensin II (Ang II) is a hormone produced as an end-product of
the renin–angiotensin system and is an important mediator of numerous
cardiovascular pathologies, such as hypertension, vascular remodelling,
and neointima formation.72 Ang II has been demonstrated to activate the
Gas6-Axl pathway and is necessary for facilitating the effects of Axl on
VSMC proliferation.73,74 In a similar vein, reactive oxygen species (ROS)
such as hydrogen peroxide (H2O2) elicit pathological effects on the
vasculature,75 at least partially through Axl in VSMCs.59 ROS have been
shown to induce interaction between Axl and glutathiolated non-muscle
myosin heavy chain (MHC)-IIB, which may mediate increased migration
in vascular injury,76 and pharmacological inhibition of Axl attenuated the
pathological effects of oxidative stress and reduced VSMC migration
in vitro.77 In addition, Axl appears to prolong VSMC survival, and Gas6
was shown to protect VSMCs from apoptosis.70,71 In this context, one
study observed increased VSMC apoptosis in Axl deficient mice, leading
to reduced intima-media thickening following ligation of the left carotid
artery.66
In addition to regulating VSMC biology, activation of Axl via Gas6
exerted a mitogenic effect on serum-starved fibroblasts in vitro and pro-
tected these cells from cell death by apoptosis.78 Similarly, Gas6-Axl signal-
ling can promote the survival and vascular endothelial growth factor A-
mediatedmigration of ECs.79–83 Finally, Axl has also been shown to directly
regulate cytokine/chemokine expression and extracellular matrix remodel-
ling in the vessel wall.84 Axl regulates these multiple aspects of vascular
function through its ability to interact with multiple downstream signalling
pathways. For example, Axl-mediated effects on cell proliferation and
migration are facilitated through activation of phosphatidylinositol-3-OH
kinase (PI3K)/protein kinase B (Akt), sarcoma (SRC) signalling pathways,
and extracellular signal-regulated kinases (ERKs), which is similar to other
RTK-mediated processes.60,61
Remarkably, differing levels of glucose in vitro can affect Axl behaviour,
demonstrated by the comparison of functional Axl interactions in
VSMCs exposed to 5.5mmol/L ‘low glucose’ or 27.5mmol/L ‘high
glucose’ culturing conditions.60 Axl was found to preferentially interact
with proteins involved in the PI3K signalling pathway under ‘low glucose’
conditions, stimulating anti-apoptotic signalling and enhancing survival of
the VSMCs. In contrast, Axl associated with signalling proteins of the
ERK1/2 pathway in ‘high glucose’ conditions, driving VSMC migration.
Ultimately, this demonstrates that the function of Axl may be altered
depending on the physiological conditions.60 In addition to this, Axl ex-
pression is significantly lower in left internal mammary artery tissue from
diabetic compared with non-diabetic patients85 and Axl overexpression
was able to reverse the effects of high glucose-induced dysfunction in
ECs in vitro.85 The precise mechanisms by which Axl signalling and func-
tion respond to varying glucose levels remains unclear. However, these
findings may have important implications in terms of understanding the
pathological effects of chronic high blood glucose levels in diabetic
patients.
Vascular calcification, which is the process by which calcium builds up
within the vasculature, is particularly prevalent in advanced, inflammatory
atherosclerosis and correlates with worse clinical outcomes.86–88
Conversely, absence of calcification in coronary arteries predicts a low
risk of CVD even in subjects with a high level of traditional risk factors.89
During calcification, vascular pericytes undergo a process of osteogenic
differentiation, and Axl was identified as one of the genes which is down-
regulated when this process was explored in vitro.90 Similarly, Axl
expression was shown to be down-regulated as cultured VSMCs calcify
their matrix, and Axl overexpression or activation inhibited calcification
in vitro.91,92 More recently, miR-34a has been shown to promote VSMC
calcification in mice and in VSMCs in vitro, with the in vitro effect of miR-
34a showing a correlation with decreased Axl expression on the cul-
tured VSMCs.93 Interestingly, work by another group has revealed that
the ability of hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reduc-
tase inhibitors (statins) to prevent phosphate-induced calcification by
VSMCs in vitro occurs via restoration of the Gas6-Axl mediated survival
pathway.94,95 Whether Axl affects vascular calcification in vivo has not yet
been determined.
Axl has also been reported to be expressed by cardiomyocytes.36 In
patients with heart failure Axl levels are amplified both in terms of the
cardiac tissue and circulating soluble Axl (sAxl).35 Furthermore, Gas6
and sAxl levels are found to increase in patients following ST-segment el-
evation MI.96 In both studies, the levels of Axl were predictive of adverse
pathology, such as the extent of left ventricular remodelling and of fur-
ther cardiovascular events. One study tested the effect of both KO and
cardiac-specific overexpression of Gas6 in a cardiac stress murine mod-
el.97 They found that Gas6-deficient mice had decreased hypertrophy, fi-
brosis, and contractile dysfunction in the chronic stress overload
induced by aortic banding. Whereas cardiac-specific overexpression of
Gas6 enhanced these pathologies. This was ultimately attributed to Gas6
activation of the ERK signalling pathway, driving cardiac hypertrophy.
Interestingly, this process was reversed with the use of a pharmacologi-
cal inhibitor of ERK. As discussed previously, Gas6 activation of Axl can
induce the ERK signalling cascade,98 which combined with evidence that
Axl levels are elevated in heart failure patients, points to the Gas6-Axl
axis as a potential novel therapeutic target in heart failure.
In summary, multiple studies suggest that GAS6/Axl drives cardiovas-
cular remodelling by regulating the biology of VSMCs, ECs, cardiomyo-
cytes, and potentially fibroblasts, thereby facilitating pathological
processes such as neointima formation, and remodelling in both the
heart and vasculature. Most importantly, Axl suppression can dampen
these adverse effects, suggesting possible therapeutic implications of
these studies.
3.2 Gas6-Axl and inflammation in CVD
Axl performs biphasic roles in the cells of the vasculature and immune
system. Axl expression has actually been suggested to drive pro-
inflammatory activation of VSMCs during vein-graft remodelling.65 In this
study, vein-graft surgeries were performed to examine the effect of Axl
deficiency in both the vein graft donor and recipient mouse to compare
the effect of vascular vs. systemic expression of Axl. The authors found
that Axl depletion in all groups led to lower levels of MHC class II ex-
pression in the vein graft, indicating lesser immune activation. They also
observed down-regulation of various pro-inflammatory cytokines and
chemokines in Axl-/- SMCs compared with Axlþ/þwith and without inter-
feron gamma (IFN-c) stimulation. Remarkably, they found Axl deficiency
to increase the expression of SOCS1 in VSMCs, i.e., opposite to what is
observed in immune cells.10,16,50
The transfer of Axl deficient haematopoietic myeloid cells to western
diet-fed low-density lipoprotein receptor KO (Ldlr-/-) mice had no effect
on atherosclerotic disease progression.99 To date no studies have exam-
ined the effect of global Axl deficiency on atherosclerosis pathology, and
thus the effect of eliminating Axl expression in the vasculature has not
been addressed. This remains an important point for study, as Axl has
been shown to be present in human vessels with expression down-regu-
lated in atherosclerotic plaques compared with normal carotids.100
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Furthermore, Axl expression is higher in vessels that are less prone to
develop atherosclerosis such as the left internal mammary artery com-
pared with the aorta.101 Concomitantly, elevated serum levels of sAxl
have been detected in the setting of acute coronary syndromes.102 The
Axl ligand Gas6 is expressed by ECs, VSMCs, and macrophages and its
expression increases with atherosclerosis development.103,104 Genetic
KO ofGas6 increases plaque stability in ApoE-/- mice, leading to increased
plaque content of SMCs and collagen and to reduced numbers of macro-
phages.105 However, data from an epidemiological studies showed that
low levels of Gas6 correlate with increased risk of coronary artery dis-
ease (CAD) in patients with psoriasis.106
An interesting study used chimeric mice with haematopoietic or non-
haematopoietic Axl deficiency to dissect the role of Axl expression in
immune vs. vasculature cells in hypertension.67 The data indicated that
Axl-expressing immune cells drove pro-inflammatory gene expression
and increased immune cell infiltration in the kidney at early stages of hy-
pertension and that Axl expression in both immune and vascular cells
was detrimental in the later phases of hypertensive disease. Continuing
on from this, the same group demonstrated that Axl is critical for survival
of T lymphocytes, affecting vascular remodelling and inflammation in
DOCA-salt induced hypertension.107
Axl has been suggested to influence natural killer (NK) cell develop-
ment. However, this conclusion is controversial, with studies supporting
a role for Axl in both the suppression and promotion of NK cells.108–110
Although none of these studies are focused on cardiovascular disease,
this could be an interesting area of future study. On the one hand, NK
cells may have a potentially protective role in CAD based on strong cor-
relations between coronary heart disease and low NK levels in
humans.111,112 However, animal studies suggest that NK cells are athe-
rogenic.113 The role of Axl in NK cells and the role of NK cells them-
selves in cardiovascular disease represent areas that will benefit from
further studies, which is necessary for a better understanding of Axl’s
role in vascular pathology and its potential as a therapeutic target.
4. MerTK in CVD
4.1 MerTK-mediated efferocytosis in
atherosclerosis
MerTK deficiency leads to enhanced pathology in mouse models of athe-
rosclerosis.30,32 One study backcrossed MerTK KOs into ApoE-/- mice,
which were maintained on western diet for either 10 or 16weeks to ex-
amine the differential effect of MerTK deficiency on early or advanced
lesions.32 The pathological effects of MerTK-deficiency were apparent in
advanced, as opposed to early, lesions owing to a marked decrease in
the clearance of apoptotic bodies and the subsequent accelerated plaque
necrosis. Interestingly, the study found no apparent effect on overall le-
sion size or plasma cholesterol profile, despite other studies showing
that effective efferocytosis is beneficial early on in lesion devel-
opment.25–27 Thus, other phagocytic receptors may play a role in effero-
cytosis in early atherosclerosis, although Axl is not likely among these
receptors, as mentioned above, the transfer of Axl deficient bone mar-
row cells to Ldlr-/- mice had no effect on atherosclerotic disease
progression.99
The effects of MerTK in atherosclerosis progression to date has been
investigated in phagocytic immune cells—primarily macrophages. This
can be inferred from a study which utilized a chimeric mouse model, in
which bone marrow cells deficient in MerTK were transferred into Ldlr-/-
mice.30 Similar to the previous study, MerTK deficiency lead to
significantly higher levels of apoptotic debris accumulation within the pla-
que after 15weeks of western diet. The authors were also able to show
increased inflammation in the lesions of these mice. In this study, there
was a 60% increased lesion size in theMertk-/- Ldlr-/- mice compared with
Mertkþ/þ Ldlr-/-. It is possible the differences in effect on lesion size may
be due to differences between the mouse models and/or composition of
the diets used in the two studies. More recently, a macrophage Ca2þ/cal-
modulin-dependent protein kinase IIc (CaMKIIc) pathway was shown to
play a key role in the development of necrotic atherosclerotic plaques
by preventing MerTK expression through the inhibition of the transcrip-
tion factors ATF6 and LXRa.114
MerTK is expressed in macrophages in human atherosclerotic
arteries,100 and MerTK induction is required for clearance of apoptotic
cells by human macrophages.115 Interestingly, it has been suggested that
macrophage MerTK deficiency can occur near the necrotic cores of hu-
man plaques via the action of ADAM17-mediated MerTK cleavage.55
ADAM17 can be activated by the byproducts of polyunsaturated fatty
acid oxidation and by inflammatory mediators, which are known to be
present within the necrotic core of atherosclerotic plaques.53,55 Levels
of sMer within individual plaques were shown to correlate with the
extent of necrosis, and mice expressing genetically modified MerTK re-
sistant to cleavage (MerTKD483-488) showed improved lesional efferocy-
tosis, more stable plaques, and, interestingly, improved resolution of
inflammation31 (see below).
Although research in this area has mainly focused on the role of
MerTK in macrophages, it should also be noted that brain microvascular
ECs have been shown to express MerTK,116 and that it is required for
tightening the blood–brain barrier during viral infection.117 In atheroscle-
rosis, inflammation and oxidative stress can destabilize the endothelial
barrier, contributing to pathology.118 Therefore, MerTK, by maintaining
the integrity of the endothelial barrier, may in principle also contribute
to impeding the development of atherosclerosis; however, further work
needs to be done to explore this aspect.
4.2 MerTK-mediated efferocytosis in
myocardial infarction
Another important facet of cardiovascular pathology that relies on effi-
cient efferocytosis, includes the clearing of dead cardiomyocytes follow-
ing MI.119–121 This process is orchestrated by various immune cells, and
the inflammatory profile of these cells can have a major influence on the
functional outcome and subsequent progression of heart failure.122
MerTK-expressing monocyte/macrophages are key for the clearance of
injured cardiomyocytes and improve remodelling following MI in
mice.123 Conversely, genetic deficiency of MerTK led to an increase in
the accumulation of apoptotic cardiac cells following experimental MI,
resulting in larger infarct sizes and worse cardiac functional outcomes.124
Cardiac extracts from the Mertkþ/þ control mice showed the presence
of sMer following MI, which is likely due to the presence of post-MI
ADAM17-activating factors that promote MerTK cleavage.125
In a study investigating adverse effects of post-MI ischaemia–reperfu-
sion (IR) in mice and humans using therapeutic interventions to restore
blood-flow, such as coronary stents and thrombolytic agents,126,127 se-
rum levels of sMer were found to be elevated.56 In the mouse models,
this finding correlated with lower expression of intact MerTK on the sur-
face of cardiac macrophages. The study went on to show that mice pos-
sessing genetically modified cleavage-resistant MerTK (MerTKD483-488)
displayed improved levels of efferocytosis, reduced infarct size, and im-
proved cardiac function following IR. It was concluded that the crucial
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role of MerTK in facilitating phagocytic clearance of cardiac debris
following MI was hindered by IR-induced MerTK cleavage. They hypoth-
esized that the trigger for this was recruitment of monocytes from the
circulation, which they tested by treating mice with an antagonist to
block C-C chemokine receptor type 2 (CCR2), a chemokine receptor
expressed by infiltrating circulatory monocytes, but not in cardiac-
resident macrophages. This treatment improved post-IR infarct size in
Mertkþ/þ but not Mertk-/- mice, suggesting that CCR2-mediated infiltra-
tion negatively affects ability of MerTK to effectively drive phagocytic
repair following IR. The exact mechanism for CCR2-dependent MerTK
cleavage is still ambiguous. One suggestion is activation of ADAM17-
mediated cleavage of MerTK by CCR2þ monocyte production of
ROS.53,55,56
Interestingly, dying cardiomyocytes in the setting of MI promote
the release of MerTK from the surface of macrophages, which prevents
engulfment of dying cardiomyocytes.125 The mechanism involves up-
regulation on cardiomyocytes of the ‘don’t-eat-me’ marker CD47 fol-
lowing MI.128 Although this process during MI is pathologic, as uncleared
apoptotic cardiomyocytes drive cardiac inflammation and further cardio-
myocyte death, it should be noted that in non-pathological conditions,
evading efferocytosis may preserve cardiomyocyte numbers in view of
their normally low regenerative capacity. In the pathologic setting of MI,
treatment with anti-CD47 subsequently enhanced cardiomyocyte
phagocytosis and reduced infarct size.128 Accordingly, further investiga-
tion into themechanism by which cardiomyocytes facilitate MerTK shed-
ding and how this can be prevented may present a novel target for
therapeutic intervention in improving post-MI recovery.
4.3 MerTK mediated resolution of
inflammation in atherosclerosis
The MerTK studies in the Apoe-/- and chimeric Ldlr-/- atherosclerosis
models found a heightened inflammatory pathology associated with loss
of MerTK.30,32 Ait-Oufella et al. showed that ex vivo cultured splenocytes
from Mertk-/- mice had increased production of pro-inflammatory cyto-
kines IFN-c, IL-12, and tumour necrosis factor (TNF)-a and decreased
production of anti-atherogenic IL-10, showing this phenotype to be in-
herent in these cells and not just a consequence of the defective apopto-
tic debris clearance. Mice expressing cleavage-resistant MerTK generate
increased levels of specialized pro-resolving mediators such as TGF-b
and IL-10 and lipid mediators such as resolvins in atherosclerotic
lesions,31,37 which, together with enhanced efferocytosis, contribute to
attenuation of cardiovascular pathology in atherosclerosis. In terms of
lipid mediators, when MerTK engages a ligand, a particular tyrosine resi-
due in the cytoplasmic tail of MerTK signals inhibition of a calcium/
CaMKII pathway that normally favours the biosynthesis of long-chain un-
saturated fatty acid-derived inflammatory mediators, notably leuko-
trienes, over resolution mediators such as lipoxins and resolvins.37,62
Thus, MerTK signalling increases the ratio of pro-resolving-to-pro-
inflammatory lipid mediators.
Activation of LXR expression occurs as a result of apoptotic cell clear-
ance, particularly in the presence of excess-lipoprotein derived choles-
terol, as would be expected within advanced atherosclerotic lesions.129
This process has been shown to promote expression of MerTK, which
mitigates pro-inflammatory cytokine release upon subsequent exposure
to cholesterol-loaded apoptotic macrophages.24,130 In addition, human
protein S inhibits the expression of macrophage scavenger receptor A
through MerTK, leading to reduced uptake of modified lipoproteins.131
Therefore, MerTK appears to sit at the interface between lipid
metabolism and inflammation within the plaque and functions to attenu-
ate inflammation in this environment.
5. Tyro3 in CVD
Apart from a study showing an association between Tyro3 and MerTK
variants and carotid atherosclerosis,132 the net contribution of Tyro3 to
CVD has not been addressed to date. This may be because Tyro3 is
mainly localized to the central nervous system and reproductive organs,
and doesn’t show high levels of expression in the vasculature.36,133,134
It’s ligand Pros1 has been found to correlate with coronary heart disease
risk and is expressed in atherosclerotic lesions.100,135
Interestingly, Tyro3 is believed to negatively regulate T helper type 2
(Th2) cells via the suppression of a specific subset of CD11cþ DCs
expressing programmed cell death protein 2 (PDL2).136 PDL2þDCs are
associated with driving Type 2 (Th2-driven) immune responses, and ex-
pression of Tyro3 in these cells was shown to decrease their Th2-
associated molecule production. This pathway functions as part of a neg-
ative feedback loop, whereby Th2-associated cytokine IL-4 induces sus-
tained expression of Pros1, which then activated Tyro3-mediated
suppression of Th2 activation. In terms of relevance to CVD, while IL-4
and IL-5 have been shown to be atheroprotective,137,138 IL-9 may be
pro-atherogenic.139 IL-13 production exerts adverse effects on cardio-
vascular pathology by driving fibrosis of heart tissue in the context of
both ageing and IR injury,140–142 but IL-13 secreted by regulatory T cells
may actually promote efferocytosis in atherosclerotic lesions.143 These
combined observations provide a strong rationale for future studies on
the role of Tyro3 in CVD.
6. Conclusions and future questions
The TAM receptors—particularly MerTK and Axl—appear to have very
different roles in suppressing or driving elements of cardiovascular pa-
thology (Figure 2). In terms of what is currently known, MerTK is funda-
mentally protective in its role. This is mediated by distinct but
complementary functions: suppression of the inflammatory response,
enhancing the inflammation resolution response, and facilitating the
clearance of apoptotic cell debris. By these criteria, as well as the protec-
tive role of MerTK in the heart itself, enhancing MerTK synthesis or func-
tioning, and/or blocking its cleavage, may represent novel therapeutic
approaches to CVD. However, this approach must consider the possible
adverse effects of heightened MerTK function on cancer144,145 and possi-
bly pathologic liver fibrosis.146
There is controversy within the literature in terms of a protective vs. a
detrimental role of Axl in CVD. This largely stems from apparent differ-
ences in Axl function, particularly in terms of activating inflammation and
the cell type in which it is expressed.While there is a molecular signalling
pathway by which Axl has been shown to suppress the immune re-
sponse, the role of this anti-inflammatory pathway in vascular cells is con-
troversial.16,65 On the other hand, Axl signalling may be protective
against vascular calcification.90,91,95 Therefore, future work will be re-
quired to sort out the mechanisms that facilitate Axl’s opposing roles in
vascular and immune cell types and how these roles affect overall cardio-
vascular pathology.
Tyro3 remains to be the least studied of the TAM receptors, particu-
larly in the area of cardiovascular disease. Other than one study which
found an association of a Tyro3 SNP in carotid atherosclerosis132
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..we could find no published work to date investigating the role of Tyro3
in the context of cardiovascular pathology. However, Tyro3may possess
a protective function in its ability to suppress of type 2 immune
responses, which promotes cardiac fibrosis.140–142 Thus, with further
work in this area, it is possible that targeting Tyro could be considered as
a fibrosis-preventing therapy post-cardiac injury.
Finally, there are studies suggesting the Gas6/TAM signalling
pathway is essential for platelet activation and thrombus stabilization.
For example, mice deficient in Gas6 or TAM receptors or treated
with inhibitors of Gas6/TAM receptor pathways develop less arterial
and venous thrombosis. The GAS6/TAM receptor role in haemostasis
and thrombosis has been recently fully reviewed elsewhere147 and is
therefore not the focus of the current review. Nonetheless, this
role of TAM receptors needs to be considered in view of the key
contribution of thrombosis to atherosclerosis and its clinical
complications.
Figure 2 Roles of TAM receptors in various cardiovascular diseases. Pathological roles for TAM receptor family members in cardiovascular disease are
shown in red, with protective roles depicted in green. MerTK-deficiency has been shown to be detrimental in atherosclerosis models owing to its ability to
dampen inflammation, promote resolution, and drive clearance of apoptotic bodies in the plaque necrotic core.30,32,56,130 These processes can be inhibited by
MerTK cleavage, which occurs in necrotic, inflammatory plaques.31,55,56 In hypertension models, Axl expression in both vascular and immune cells has been im-
plicated to drive pro-inflammatory responses in the kidney,67 and to affect T cell survival, vascular inflammation and remodelling.107 A major contribution to
heart failure in coronary heart disease is due to tissue damage and fibrosis following myocardial infarction. Efficient clearing of dead cardiomyocytes is crucial for
restoration of cardiac function, andMerTK has been shown to play a protective role in this setting.124 This process can be hindered by cleavage of MerTK, which
is increased following ischaemia–reperfusion.56 Although Tyro3 could potentially have a protective effect on the myocardium, as it suppresses Th2 responses
which drive cardiac fibrosis,136,140–142 a direct causal link has not been shown to date. Gas6-Axl driven activation of the ERK signalling cascade in cardiomyocytes
is implemented in the pathological remodelling which occurs in heart failure patients.35,96,97 Numerous studies have highlighted Axl to also have a pathological
role in vascular remodelling through increasing VSMC proliferation, migration, and immune activation, while also inhibiting VSMC apoptosis.64,65,69,79
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